Liver cancer is the second leading cause of cancer-related deaths worldwide. Due to this, there is a need for more predictive and relevant preclinical models to provide better insights into clinical outcomes when evaluating new cancer therapies. Patient-derived xenograft (PDX) models display a true representation of the human genetic and phenotypic heterogeneity seen in patient populations and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. Crown Bioscience’s collection consists of a large number of liver cancer PDX models, including several orthotopic models to more closely recapitulate the tumor microenvironment. More